TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
Merck Life Science AB
Closing information (x1000 EUR)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
103,843
|
116,118
|
118,864 |
| Financial expenses |
16
|
0
|
110 |
| Earnings before taxes |
55,345
|
63,166
|
63,894 |
| EBITDA |
52,758
|
59,679
|
63,562 |
| Total assets |
68,899
|
129,430
|
82,458 |
| Current assets |
67,700
|
128,183
|
81,129 |
| Current liabilities |
4,046
|
8,642
|
11,963 |
| Equity capital |
63,901
|
119,816
|
69,524 |
| - share capital |
897
|
928
|
926 |
| Employees (average) |
40
|
48
|
46 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
92.7%
|
92.6%
|
84.3% |
| Turnover per employee |
2,596
|
2,419
|
2,584 |
| Profit as a percentage of turnover |
53.3%
|
54.4%
|
53.8% |
| Return on assets (ROA) |
80.4%
|
48.8%
|
77.6% |
| Current ratio |
1673.3%
|
1483.3%
|
678.2% |
| Return on equity (ROE) |
86.6%
|
52.7%
|
91.9% |
| Change turnover |
-8,327
|
-3,092
|
35,362 |
| Change turnover % |
-7%
|
-3%
|
42% |
| Chg. No. of employees |
-8
|
2
|
17 |
| Chg. No. of employees % |
-17%
|
4%
|
59% |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.